Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience

5 Feb 2019

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Share to Lung Cancer Research Studies
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30735816
DOI: 10.1016/j.jtho.2019.01.020

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 21 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium ExperiencePMID 30735816Read ↗

Mutational Characteristics and Clinical Outcomes for Lung Adenocarcinoma With EGFR Germline MutationsSemantic proximity Read ↗

Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomesSemantic proximity Read ↗

Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.Semantic proximity Read ↗

Impact of KRAS and EGFR Gene Mutations on Recurrence and Survival in Patients with Surgically Resected Lung AdenocarcinomasSemantic proximity Read ↗

Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorsSemantic proximity Read ↗

New Horizons in KRAS-Mutant Lung Cancer: Dawn After DarknessSemantic proximity Read ↗

Outcomes After Surgical Resection of Early-stage Lung Adenocarcinomas With Epidermal Growth Factor Receptor Mutations.Semantic proximity Read ↗

Clinical presentation and outcomes according to KRAS status in advanced non-small cell lung cancerSemantic proximity Read ↗

Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung.Semantic proximity Read ↗

Clinical characteristics and course of 63 patients with BRAF mutant lung cancers.Semantic proximity Read ↗

Clinical characteristic and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French real-life ESME cohort.Semantic proximity Read ↗

Spectrum of KRAS variants in primary lung mucinous adenocarcinoma: implications for diagnosis, testing, and therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.